ストックスクリーナーアプリを入手
251.39
3.54%
8.79
Axsome Therapeutics Inc (AXSM) 最新ニュース
RBC Capital Adjusts Axsome Therapeutics Price Target to $304 From $302, Maintains Outperform Rating - marketscreener.com
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD) - The Manila Times
Axsome doses first patient in pediatric ADHD trial By Investing.com - Investing.com Canada
Axsome starts Phase 3 ADHD trial in children, enrolling 468 patients - Stock Titan
Sleep Apnea Pipeline 2026: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Apnimed, Eli Lilly, Incannex Healthcare, Axsome Therapeutics, Jazz Pharma, Bioprojet - Barchart.com
These 3 Stocks Trounced the S&P 500 in the First Half of 2026 -- and Wall Street Thinks 1 of Them Could Soar Even More - The Motley Fool
Responsive Playbooks and the AXSM Inflection - Stock Traders Daily
Axsome Therapeutics’ Q4 Numbers Beat Wall Street Expectations: Analyst Sees Over 23% Upside For Stock - Stocktwits
The Bull Case For Axsome Therapeutics (AXSM) Could Change Following Phase 3 ADHD Trial And Index Moves - simplywall.st
HB Wealth Management LLC Grows Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
SG Americas Securities LLC Has $1.25 Million Stock Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
If You Invested $1,000 in Axsome Therapeut (AXSM) - Stock Titan
Is Axsome Therapeutics Stock a Millionaire Maker? Here's What the Numbers Say. - Yahoo Finance
Axsome Therapeutics(AXSM.US) 10% Shareholder Sells US$11.93 Million in Common Stock - Moomoo
Axsome therapeutics CEO Herriot Tabuteau sells $11.9 million in shares - Investing.com UK
Form 4 Axsome Therapeutics Inc For: 1 July By Investing.com - Investing.com Canada
Axsome therapeutics CEO Herriot Tabuteau sells $11.9 million in shares By Investing.com - Investing.com South Africa
Axsome Therapeutics (AXSM) CEO sells 49,666 exercised shares under 10b5-1 plan - Stock Titan
Form 144 Axsome Therapeutics For: 1 July By Investing.com - Investing.com Canada
Form 144 | Axsome Therapeutics(AXSM.US) Officer Proposes to Sell 11.95 Million in Common Stocks - Moomoo
49,666-share sale notice for AXSM (NASDAQ: AXSM) via cashless exercise - Stock Titan
Why Axsome Stock Has Doubled In Nine Months - Yahoo! Finance Canada
AXSM Stock Is Rising Today After Wall Street’s Positive Stance Despite Mixed Q1 – What's Behind The Optimism? - Stocktwits
Pictet Asset Management Holding SA Sells 20,080 Shares of Axsome Therapeutics, Inc. $AXSM - MarketBeat
Sleep Apnea Market Expected to Experience Accelerated Growth and Market Evolution by 2034 – DelveInsight | Apnimed, Eli Lilly, Incannex Healthcare, Axsome Therapeutics, Jazz Pharma, Bioprojet - Barchart.com
Axsome Therapeutics, Inc.(NasdaqGM: AXSM) dropped from Russell 2000 Index - marketscreener.com
Axsome Therapeutics, Inc.(NasdaqGM: AXSM) added to Russell Midcap Growth Benchmark - marketscreener.com
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Is Expected To Breakeven In The Near Future - Moomoo
Axsome Therapeutics, Inc.(NasdaqGM:AXSM) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Strong Buy Ratings Signal Potential Upside In Biotech Sector - DirectorsTalk Interviews
Axsome Therapeutics, Inc.(NasdaqGM: AXSM) added to Russell 1000 Growth Benchmark - marketscreener.com
Axsome Therapeutics, Inc.(NasdaqGM: AXSM) dropped from Russell 2000 Dynamic Index - marketscreener.com
Axsome Therapeutics, Inc.(NasdaqGM: AXSM) added to Russell 1000 Dynamic Index - marketscreener.com
AXSM Stock In Spotlight Ahead Of Key FDA Verdict On Alzheimer’s Drug This Week - Stocktwits
Price to sales forward of Axsome Therapeutics, Inc. – NASDAQ:AXSM - TradingView
Price to sales forward of Axsome Therapeutics, Inc. – LSX:A2AA7B - TradingView
Axsome doses first patient in phase 3 ADHD trial By Investing.com - Investing.com Australia
Price to earnings forward of Axsome Therapeutics, Inc. – NASDAQ:AXSM - TradingView
Price to earnings forward of Axsome Therapeutics, Inc. – LSX:A2AA7B - TradingView
Axsome Therapeutics (AXSM) Initiates FOCUS-3 Trial for ADHD Trea - GuruFocus
Axsome Therapeutics doses first patient in FOCUS-3 phase 3 ADHD trial - grafa.com
Axsome doses first patient in phase 3 ADHD trial - Investing.com UK
Axsome starts Phase 3 trial of solriamfetol for ADHD in adolescents, aiming to improve treatment options. - Pluang
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD) - The Manila Times
Axsome starts 468-patient ADHD trial for teens - Stock Titan
Axsome Therapeutics, Inc. Actuals & Estimates (NASDAQ:AXSM) - TradingView
Axsome Therapeutics, Inc. Actuals & Estimates (FWB:19X) - TradingView
Price to book forward of Axsome Therapeutics, Inc. – NASDAQ:AXSM - TradingView
Price to book forward of Axsome Therapeutics, Inc. – LSE:0HKF - TradingView
Enterprise value to EBITDA forward of Axsome Therapeutics, Inc. – LSE:0HKF - TradingView
Enterprise value to revenue forward of Axsome Therapeutics, Inc. – NASDAQ:AXSM - TradingView
Assenagon Asset Management S.A. Grows Stock Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
Price to earnings forward of Axsome Therapeutics, Inc. – LSE:0HKF - TradingView
Understanding the Setup: (AXSM) and Scalable Risk - Stock Traders Daily
Axsome Therapeutics Inc (AXSM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Definium's LSD-based depression pill delivers strong late-stage results, shares surge - Reuters
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: A Biotech Leader with 57.4% Revenue Growth and Strong Buy Ratings - DirectorsTalk Interviews
Axsome Therapeutics Inc (AXSM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Enterprise value of Axsome Therapeutics, Inc. – XETR:19X - TradingView
Virtu Financial LLC Invests $2.84 Million in Axsome Therapeutics, Inc. $AXSM - MarketBeat
12,955 Shares in Axsome Therapeutics, Inc. $AXSM Purchased by Seven Fleet Capital Management LP - MarketBeat
Axsome Therapeutics Inc (AXSM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Axsome Therapeutics Inc (AXSM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Axsome Therapeutics Inc (AXSM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AXSM Stock Clocks Best Day In About 4 Months On FDA Greenlight For Alzheimer’s Drug - Stocktwits
1.95%
2.70%
大文字化:
|
ボリューム (24 時間):